PE20142456A1 - COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks - Google Patents
COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3KsInfo
- Publication number
- PE20142456A1 PE20142456A1 PE2014001291A PE2014001291A PE20142456A1 PE 20142456 A1 PE20142456 A1 PE 20142456A1 PE 2014001291 A PE2014001291 A PE 2014001291A PE 2014001291 A PE2014001291 A PE 2014001291A PE 20142456 A1 PE20142456 A1 PE 20142456A1
- Authority
- PE
- Peru
- Prior art keywords
- oxazolidin
- ona
- inhibitors
- pi3ks
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
REFERIDA A UN COMPUESTO OXAZOLIDIN-2-ONA DE FORMULA (I), DONDE R1 ES UN GRUPO (a) O (b); R1a ES H O CH3; D ES DEUTERIO; R2 ES H, CH3, CH2OH, CH2OCH3, ENTRE OTROS; R3 ES H; R4 ES H, CH2OH, CH3, ENTRE OTROS; R5 ES H, CH3, CH2OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-3-(2'-AMINO-2-MORFOLIN-4-IL-4'-TRIFLUOROMETIL-[4,5']BIPIRIMIDINIL-6-IL)-4-METIL-OXAZOLIDIN-2-ONA, (S)-3-(2'-AMINO-2-MORFOLIN-4-IL-4'-TRIFLUOROMETIL-[4,5']BIPIRIMIDINIL-6-IL)-4-HIDROXIMETIL-5,5-DIMETIL-OXAZOLIDIN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS ACTUAN COMO INHIBIDORES DE LA PI3K (FOSFATIDILINOSITOL-3-QUINASA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261602954P | 2012-02-24 | 2012-02-24 | |
US201261736707P | 2012-12-13 | 2012-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142456A1 true PE20142456A1 (es) | 2015-01-14 |
Family
ID=48142031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001291A PE20142456A1 (es) | 2012-02-24 | 2013-02-22 | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks |
Country Status (31)
Country | Link |
---|---|
US (2) | US8865894B2 (es) |
EP (1) | EP2817307B1 (es) |
JP (1) | JP6154404B2 (es) |
KR (1) | KR101640698B1 (es) |
CN (1) | CN104144926B (es) |
AP (1) | AP2014007835A0 (es) |
AR (1) | AR090121A1 (es) |
AU (1) | AU2013223713C1 (es) |
BR (1) | BR112014020672B1 (es) |
CA (1) | CA2865372A1 (es) |
CO (1) | CO7051028A2 (es) |
CR (1) | CR20140397A (es) |
DO (1) | DOP2014000194A (es) |
EA (1) | EA026031B1 (es) |
ES (1) | ES2598118T3 (es) |
GE (1) | GEP20156389B (es) |
GT (1) | GT201400178A (es) |
HK (1) | HK1199643A1 (es) |
IL (1) | IL233936A (es) |
MX (1) | MX353341B (es) |
NI (1) | NI201400089A (es) |
NZ (1) | NZ629198A (es) |
PE (1) | PE20142456A1 (es) |
PH (1) | PH12014501900A1 (es) |
PL (1) | PL2817307T3 (es) |
PT (1) | PT2817307T (es) |
SG (1) | SG11201404794XA (es) |
TW (1) | TW201339155A (es) |
UY (1) | UY34632A (es) |
WO (1) | WO2013124826A1 (es) |
ZA (1) | ZA201405446B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20141581A1 (es) | 2011-09-27 | 2014-11-14 | Novartis Ag | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
ES2719136T3 (es) | 2014-03-24 | 2019-07-08 | Novartis Ag | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas |
TW201609108A (zh) | 2014-07-25 | 2016-03-16 | 諾華公司 | 醫藥劑型 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
WO2016064958A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors |
EP3209664B1 (en) | 2014-10-22 | 2020-06-03 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
WO2017001658A1 (en) * | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
CN107873032B (zh) * | 2015-07-02 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
CN109923117A (zh) * | 2016-11-02 | 2019-06-21 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
JP7433910B2 (ja) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Cd73に対する抗体分子及びその使用 |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
EP3728230A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
CN109134558A (zh) * | 2018-09-21 | 2019-01-04 | 常州方圆制药有限公司 | 一种提高1-N-乙基庆大霉素Cla收率的合成方法 |
CN109970764B (zh) * | 2019-03-26 | 2021-11-09 | 上海吉奉生物科技有限公司 | 一种(S)-1,1,5,5-四甲基二氢恶唑并[3,4-c]恶唑-3-酮的合成方法 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
JPS4921148Y1 (es) | 1970-02-07 | 1974-06-06 | ||
JPS4921149Y1 (es) | 1970-06-27 | 1974-06-06 | ||
JPS4921148B1 (es) | 1970-12-28 | 1974-05-30 | ||
JPS4921149B1 (es) | 1970-12-28 | 1974-05-30 | ||
AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
WO1992000970A1 (fr) | 1990-07-03 | 1992-01-23 | Mitsui Petrochemical Industries, Limited | Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose |
JP3145410B2 (ja) | 1995-04-13 | 2001-03-12 | 大鵬薬品工業株式会社 | 新規な4,6−ジアリールピリミジン誘導体及びその塩 |
JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
AU727013B2 (en) | 1997-07-24 | 2000-11-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
DK0930302T3 (da) | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
DE69919707T2 (de) | 1998-06-19 | 2005-09-01 | Chiron Corp., Emeryville | Glycogen synthase kinase 3 inhibitoren |
US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
AU768201B2 (en) | 1999-01-22 | 2003-12-04 | Amgen, Inc. | Kinase inhibitors |
AU6605200A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
CA2376951A1 (en) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Src kinase inhibitor compounds |
US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001005783A1 (en) | 1999-07-15 | 2001-01-25 | Pharmacopeia, Inc. | Bradykinin b1 receptor antagonists |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
EP1274705A1 (en) | 2000-03-29 | 2003-01-15 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
WO2001083460A1 (fr) | 2000-04-28 | 2001-11-08 | Tanabe Seiyaku Co., Ltd. | Composes cycliques |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
BR0116411A (pt) | 2000-12-21 | 2003-11-11 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
EP1363890A4 (en) | 2001-02-07 | 2009-06-10 | Ore Pharmaceuticals Inc | MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION |
AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
JP2004531571A (ja) | 2001-05-25 | 2004-10-14 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物 |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
WO2003078423A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
DE60332433D1 (de) | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
AU2003288925A1 (en) | 2002-10-08 | 2004-05-04 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
AU2003295776B2 (en) | 2002-11-21 | 2011-05-12 | Novartis Vaccines And Diagnostics, Inc. | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
EP1608622A4 (en) | 2003-03-24 | 2009-04-01 | Merck & Co Inc | BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
EP1610774A4 (en) | 2003-04-09 | 2008-07-16 | Exelixis Inc | TIE-2 MODULATORS AND METHODS OF USE |
WO2005002514A2 (en) | 2003-06-13 | 2005-01-13 | Echelon Biosciences Incorporated | Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof |
CA2531490A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
AU2004257289A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
AU2005232745A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
JP2008523156A (ja) | 2004-12-13 | 2008-07-03 | ニューロジェン・コーポレーション | 置換ビアリール類縁体 |
CN101080228A (zh) | 2004-12-13 | 2007-11-28 | 神经能质公司 | 哌嗪基-吡啶类似物 |
US7300931B2 (en) | 2004-12-28 | 2007-11-27 | Kinex Pharmaceuticals, Llc | Compositions for treating cell proliferation disorders |
AU2006206246A1 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
KR20070108916A (ko) | 2005-02-25 | 2007-11-13 | 쿠도스 파마슈티칼스 리미티드 | Mtor 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도 |
CA2606288A1 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
BRPI0611707A2 (pt) | 2005-06-29 | 2012-04-24 | Compumedics Ltd | conjunto de sensor com ponte condutiva |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2007120897A2 (en) * | 2006-04-13 | 2007-10-25 | The Trustees Of Columbia University In The City Of New York | Compositions and intraluminal devices for inhibiting vascular stenosis |
WO2008080937A1 (en) | 2006-12-28 | 2008-07-10 | Basf Se | 2-substituted pyrimidines i in therapy |
CA2675558A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
AR067478A1 (es) | 2007-07-09 | 2009-10-14 | Astrazeneca Ab | Compuestos derivados de morfolina pirimidina |
WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
AU2009221164B2 (en) | 2008-03-05 | 2012-07-26 | Novartis Ag | Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
BRPI0909082A2 (pt) | 2008-03-26 | 2019-02-26 | Novartis Ag | imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf |
WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
US8575338B2 (en) | 2008-04-09 | 2013-11-05 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers |
GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
EP2349275B1 (en) | 2008-10-31 | 2017-03-08 | Novartis AG | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
AU2010211672B2 (en) | 2009-02-06 | 2016-08-04 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
RU2011151603A (ru) | 2009-05-19 | 2013-06-27 | ДАУ АГРОСАЙЕНСИЗ ЭлЭсСи | Соединения и способы борьбы с грибами |
EP2451802A1 (en) | 2009-07-07 | 2012-05-16 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
CA2773848A1 (en) | 2009-09-09 | 2011-03-17 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
ES2642109T3 (es) | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
ES2704862T3 (es) | 2010-07-16 | 2019-03-20 | Agios Pharmaceuticals Inc | Composiciones terapéuticamente activas y su método de uso |
KR20130119928A (ko) | 2010-10-01 | 2013-11-01 | 노파르티스 아게 | 피리미딘 유도체의 제조 방법 |
LT2629776T (lt) | 2010-10-18 | 2017-11-10 | Cerenis Therapeutics Holding Sa | Junginiai, kompozicijos ir būdai, tinkami cholesterolio mobilizavimui |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
CA2826387A1 (en) | 2011-02-11 | 2012-08-16 | Dana Farber Cancer Institute, Inc. | Method of inhibiting hamartoma tumor cells |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN103764130A (zh) | 2011-09-01 | 2014-04-30 | 诺华股份有限公司 | 用于治疗骨癌或者预防原发性癌细胞转移性播散入骨中的pi3k抑制剂 |
PE20141581A1 (es) | 2011-09-27 | 2014-11-14 | Novartis Ag | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante |
CA2851082A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
JP6381523B2 (ja) | 2012-05-16 | 2018-08-29 | ノバルティス アーゲー | Pi−3キナーゼ阻害剤の投与レジメン |
CN104349771A (zh) | 2012-06-06 | 2015-02-11 | 诺华股份有限公司 | 用于治疗肿瘤疾病的17α-羟化酶(C17,20-裂解酶)抑制剂和特定PI-3K抑制剂的组合 |
CN105050623B (zh) | 2012-08-16 | 2018-06-12 | 诺华股份有限公司 | Pi3k抑制剂和c-met抑制剂的组合 |
WO2014064058A1 (en) | 2012-10-23 | 2014-05-01 | Novartis Ag | Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2013
- 2013-02-21 UY UY0001034632A patent/UY34632A/es not_active Application Discontinuation
- 2013-02-22 AP AP2014007835A patent/AP2014007835A0/xx unknown
- 2013-02-22 PE PE2014001291A patent/PE20142456A1/es not_active Application Discontinuation
- 2013-02-22 EA EA201491579A patent/EA026031B1/ru not_active IP Right Cessation
- 2013-02-22 BR BR112014020672-4A patent/BR112014020672B1/pt active IP Right Grant
- 2013-02-22 NZ NZ629198A patent/NZ629198A/en not_active IP Right Cessation
- 2013-02-22 ES ES13717317.5T patent/ES2598118T3/es active Active
- 2013-02-22 KR KR1020147023243A patent/KR101640698B1/ko active IP Right Grant
- 2013-02-22 PT PT137173175T patent/PT2817307T/pt unknown
- 2013-02-22 AU AU2013223713A patent/AU2013223713C1/en active Active
- 2013-02-22 GE GEAP201313557A patent/GEP20156389B/en unknown
- 2013-02-22 CA CA2865372A patent/CA2865372A1/en not_active Abandoned
- 2013-02-22 JP JP2014558256A patent/JP6154404B2/ja active Active
- 2013-02-22 PL PL13717317T patent/PL2817307T3/pl unknown
- 2013-02-22 MX MX2014010141A patent/MX353341B/es active IP Right Grant
- 2013-02-22 EP EP13717317.5A patent/EP2817307B1/en active Active
- 2013-02-22 CN CN201380010698.9A patent/CN104144926B/zh active Active
- 2013-02-22 SG SG11201404794XA patent/SG11201404794XA/en unknown
- 2013-02-22 AR ARP130100536A patent/AR090121A1/es unknown
- 2013-02-22 TW TW102106331A patent/TW201339155A/zh unknown
- 2013-02-22 WO PCT/IB2013/051443 patent/WO2013124826A1/en active Application Filing
- 2013-02-22 US US13/773,947 patent/US8865894B2/en active Active
-
2014
- 2014-07-23 ZA ZA2014/05446A patent/ZA201405446B/en unknown
- 2014-08-04 IL IL233936A patent/IL233936A/en not_active IP Right Cessation
- 2014-08-12 NI NI201400089A patent/NI201400089A/es unknown
- 2014-08-15 CO CO14179492A patent/CO7051028A2/es unknown
- 2014-08-22 DO DO2014000194A patent/DOP2014000194A/es unknown
- 2014-08-22 GT GT201400178A patent/GT201400178A/es unknown
- 2014-08-22 CR CR20140397A patent/CR20140397A/es unknown
- 2014-08-22 PH PH12014501900A patent/PH12014501900A1/en unknown
- 2014-09-05 US US14/478,523 patent/US9458177B2/en active Active
-
2015
- 2015-01-02 HK HK15100012.7A patent/HK1199643A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
CR20110610A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
BR112012018345A2 (pt) | "compostos de heteroarila, bem como composições e usos dos mesmos" | |
CR20130543A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
DOP2014000156A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
DOP2011000260A (es) | Pirimidinas fusionadas | |
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
CR20150175A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
SV2011003855A (es) | Heteroarilos sustituidos | |
PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
PE20150966A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
PE20142366A1 (es) | Compuestos triazolo como inhibidores de pde 10 | |
PE20151748A1 (es) | Inhibidores de bace1 | |
UY36651A (es) | Compuestos antiestrogénicos | |
EA201491002A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
PE20151006A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |